CSIMarket
 
Integra Lifesciences Holdings Corp  (NASDAQ: IART)
Other Ticker:  
 
 
Price: $24.1800 $0.03 0.124%
Day's High: $24.5 Week Perf: 0.33 %
Day's Low: $ 23.91 30 Day Perf: -9.44 %
Volume (M): 123 52 Wk High: $ 45.42
Volume (M$): $ 2,976 52 Wk Avg: $29.51
Open: $24.07 52 Wk Low: $16.81



 Market Capitalization (Millions $) 1,849
 Shares Outstanding (Millions) 76
 Employees 3,946
 Revenues (TTM) (Millions $) 1,565
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -59
 Capital Exp. (TTM) (Millions $) 99

Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp is a leading global medical technology company that produces a wide range of innovative and advanced surgical products and devices. The company provides products and solutions for orthopedic and tissue regeneration surgeries, neurosurgery, reconstructive and general surgery, and wound care. Founded in 1989, Integra Lifesciences is headquartered in Plainsboro, New Jersey, and operates in more than 100 countries worldwide.

Products and Services:

The company produces a broad range of surgical products and devices, including:

1. Orthopedic Products: These products are used to treat and repair musculoskeletal injuries, including fractures, soft tissue injuries, and degenerative conditions. Integra Lifesciences offers a range of bone graft substitutes, fixation systems, and instruments for orthopedic surgeons.

2. Tissue Regeneration Products: These products are used to repair and regenerate tissues including skin, bone, and nerves. Integra Lifesciences offers advanced solutions for tissue engineering, wound care, and regenerative medicine.

3. Neurosurgical Products: These products are used in neurosurgery to treat conditions such as brain tumors, skull base surgery, and spinal surgery. Integra Lifesciences provides a diverse range of neurosurgical devices, including cranial fixation systems, neurosurgical instruments, and neuro-monitoring products.

4. Reconstructive and General Surgery Products: These products are used in procedures to restore function and aesthetic appearance after traumatic injuries, cancers or other diseases. Integra Lifesciences provides devices and products for reconstructive surgery of the breast, face, and abdomen.

Operating Segments:

Integra Lifesciences operates through three main segments:

1. Codman Specialty Surgical: This segment is focused on neurosurgery and provides devices and instruments for cranial, spinal, and peripheral nerve surgical procedures.

2. Orthopedics and Tissue Technologies: This segment provides products and devices for orthopedics, wound care, and tissue regeneration.

3. Private Label: This segment provides a range of surgical instruments, such as ear, nose, and throat (ENT) instruments, and surgical implants and equipment to medical device companies.

Acquisitions:

Over the years, Integra Lifesciences has made several strategic acquisitions to enhance its product portfolio and expand its market reach. In 2017, the company acquired Codman Neurosurgery from Johnson & Johnson for $1.05 billion, which includes a portfolio of surgical instruments and devices for neurosurgery.

In 2014, Integra Lifesciences acquired the Derma Sciences wound care business to expand its portfolio of wound care solutions. In 2012, the company bought Ascension Orthopedics, a manufacturer of implants for upper extremity surgical procedures.

Conclusion:

Integra Lifesciences is a leading global medical technology company that offers a wide range of innovative and advanced surgical products and devices. The company's products help surgeons and healthcare professionals to improve patient outcomes and quality of life. With a strong focus on research and development, manufacturing expertise, and global distribution network, Integra Lifesciences is well-positioned to continue providing innovative solutions for the medical industry.


   Company Address: 1100 Campus Road Princeton 8540 NJ
   Company Phone Number: 275-0500   Stock Exchange / Ticker: NASDAQ IART


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -2.78%    
BDX        3.31% 
BSX        0.55% 
MDT   -1.4%    
SYK   -2.33%    
ZBH   -1.03%    
• View Complete Report
   



Management Announcement

Integra LifeSciences Announces Plans for State-of-the-Art Manufacturing Facility in Braintree, Massachusetts, Boosting IART Shares by 5.66%

Published Mon, Jul 15 2024 12:00 PM UTC

Integra LifeSciences Aims to Boost Production with New Cutting-Edge Facility in Braintree, Massachusetts, Fuelling Growth Prospects for Investors
Integra LifeSciences, a leading global medical technology company, is set to revolutionize its manufacturing capabilities with plans to operationalize a state-of-the-art facility in Braintree, Massachusetts by the first half of...

Announcement

Integra LifeSciences: Redefining Healthcare Technology and Driving Transformation in the Industry

Published Mon, May 13 2024 8:30 PM UTC

Integra LifeSciences Holdings Corporation, a prominent global medical technology company, is set to make a significant impact at the upcoming 2024 Bank of America Healthcare Conference. Lea Knight, the company's CFO, will be presenting on Tuesday, May 14, 2024, at 4:40pm ET, shedding light on the strategic direction and vision for the company's future.Integra LifeSciences Ho...

Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp Reports Revenue Decrease in First Quarter of 2024

Integra LifeSciences Holdings Corporation, a leading global medical technology company, recently announced its financial results for the first quarter ending March 31, 2024. The company reported a deficit of $-0.04 per share, compared to $0.29 per share a year ago. Additionally, earnings per share fell from $0.25 in the prior quarter. Revenue also saw a decline of -3.144% to $368.87 million from $380.85 million in the corresponding quarter a year ago and sequentially, revenue deteriorated by -7.094% from $397.04 million. This fall in business is not comparable to the relative growth seen in the Medical Equipment & Supplies sector during the same period.
Integra Lifesciences Holdings Corp also logged a net deficit of $-3.281 million for the first quarter of 2024, a significant difference from the net proceeds of $24.226 million achieved in the corresponding quarter the previous year. Operating earnings fell by -89.1% to $3.964 million, leading to a decrease in the company's operating margin from 9.55% in the first quarter of 2023 to 1.07% in 2024.

Product Service News

Integra LifeSciences Presents Revolutionary CereLink ICP Monitoring System at AANS Annual Scientific Meeting

Published Tue, Apr 30 2024 8:20 PM UTC

Integra LifeSciences: Revolutionizing Intracranial Pressure Monitoring at AANS Annual Scientific MeetingChicago, Illinois - The American Association of Neurological Surgeons (AANS) Annual Scientific Meeting is set to witness a groundbreaking advancement in the field of intracranial pressure (ICP) monitoring. Integra LifeSciences, a leading global medical technology company, ...

Merger and Acquisition

Integra LifeSciences Expands Market Dominance: Acquiring Acclarent, Inc. Sets the Stage for Future Growth

Published Mon, Apr 1 2024 8:16 PM UTC

Integra LifeSciences Expands Market Leadership with Acquisition of Acclarent, Inc.
Integra LifeSciences Holdings Corporation, a prominent global medical technology company, has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose, and throat (ENT) surgical interventions. This strategic move bolsters Integra's leading position in the medical d...







Integra Lifesciences Holdings's Segments
Codman Specialty Surgical    71.1 % of total Revenue
Codman Specialty Surgical Neurosurgery    46.2 % of total Revenue
Codman Specialty Surgical Instruments    14.24 % of total Revenue
Codman Specialty Surgical ENT    10.66 % of total Revenue
Tissue Technologies    28.9 % of total Revenue
Tissue Technologies Wound Reconstruction and Care    21.13 % of total Revenue
Tissue Technologies Private Label    7.77 % of total Revenue
United States    76.2 % of total Revenue
Europe    9.02 % of total Revenue
Asia Pacific    9.73 % of total Revenue
Rest of World    5.05 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com